74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Ocular Therapeutix Inc
Closed
SectorHealthcare
7.9 0.77
Overview
Share price change
24h
Min
7.7
Max
7.97
Income | -12M -48M |
|---|---|
Sales | 1.7M 17M |
EPS | -0.29 |
Profit margin | -283.269 |
Employees | 274 |
EBITDA | -12M -44M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +125.48% upside |
Next Earnings | 6 May 2025 |
|---|
Market Cap | 279M 1.2B |
|---|---|
Previous open | 7.13 |
Previous close | 7.9 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Ocular Therapeutix Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Ocular Therapeutix Inc Forecast
Price Target
By TipRanks
125.48% upside
12 Months Forecast
Average 17.7 USD 125.48%
High 22 USD
Low 14 USD
Based on 10 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
